Search results
US FDA extends review of Ascendis Pharma's hormone disorder therapy
Reuters· 5 days ago, opens new tab therapy to treat adult patients with a hormone disorder by three months, the company...
To aim for £1,000 a month in passive income, should I buy growth shares or value shares?
Motley Fool UK· 3 days agoGrowth shares and value shares both offer returns that can equate to a decent amount of monthly...
How the love story between von der Leyen and Pfizer turned sour
Euronews via Yahoo News UK· 2 days agoFrom making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and...
Who earns the most, CEOs or sports stars? It depends where you live
Fortune via Yahoo Finance UK· 2 days agoThat honor, according to analysis by the U.K.’s High Pay Centre, an independent think tank, goes to...
Nicola Sturgeon & John Swinney 'Covid control freaks' as cases hit record high
The Scottish Sun· 17 hours agoNICOLA Sturgeon and John Swinney were accused of being Covid control freaks — after it was revealed...
'Choose France' investment push bags record $16 billion in pledges
Reuters· 6 days agoFrance won a record 15 billion euros ($16.17 billion) in foreign investment pledges on Monday,...
India's Mankind Pharma's Q4 profit jumps on strength in chronic drugs segment
Reuters· 4 days agoIndian pharmaceutical company Mankind Pharma posted a more than 65% rise in its fourth-quarter...
Amazon Web Services ASEAN BrandVoice: Why You Need To Invest In Cloud And AI Talent Now
Forbes· 6 days agoThe emergence of powerful cloud-enabled technologies like artificial intelligence (AI) and machine...
Anglo American raises the stakes - ALEX BRUMMER
This Is Money· 5 days agoAnglo American has dug deep and come up with a convincing plan to preserve independence. Word is that much of its strategy –divestment of De Beers and...
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance UK· 2 days agoImage Source: Zacks Investment Research In the last five trading sessions, Novo Nordisk rose the...